| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 3,773 | 11,481 | ||
| General and administrative | 2,602 | 2,497 | ||
| Total operating expenses | 6,375 | 13,978 | ||
| Interest expense | - | -3 | ||
| Loss from operations | -6,375 | -13,978 | ||
| Grant income | 1,215 | 7,106 | ||
| Other income, net | 230 | 141 | ||
| Total other income, net | 1,445 | 7,244 | ||
| Net loss | -4,930 | -6,734 | ||
| Total comprehensive loss | -4,930 | -6,734 | ||
| Earnings per share, basic | -0.06 | -0.11 | ||
| Earnings per share, diluted | -0.06 | -0.11 | ||
| Weighted average number of shares outstanding, basic | 77,951,513 | 63,690,945 | ||
| Weighted average number of shares outstanding, diluted | 77,951,513 | 63,690,945 | ||
COGNITION THERAPEUTICS INC (CGTX)
COGNITION THERAPEUTICS INC (CGTX)